These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 4568964

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Tumor suppression by cell walls of mycobacterium bovis attached to oil droplets.
    Zbar B, Rapp HJ, Ribi EE.
    J Natl Cancer Inst; 1972 Mar; 48(3):831-5. PubMed ID: 4333775
    [No Abstract] [Full Text] [Related]

  • 23. Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG).
    Zbar B, Bernstein I, Tanaka T, Rapp HJ.
    Science; 1970 Dec 11; 170(3963):1217-8. PubMed ID: 4920656
    [Abstract] [Full Text] [Related]

  • 24. Tumor regression mediated by Mycobacterium bovis (strain BCG).
    Zbar B.
    Natl Cancer Inst Monogr; 1972 Dec 11; 35():341-4. PubMed ID: 4572832
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Abrogation of tumor rejection by trypan blue.
    Kreider JW, Bartlett GL, DeFreitas E.
    Cancer Res; 1978 Apr 11; 38(4):1036-40. PubMed ID: 205342
    [Abstract] [Full Text] [Related]

  • 27. Effect of Bacillus Calmette-Guérin on the development of primary lung cancer in Syrian golden hamsters.
    Zwilling BS, Davis GW.
    Cancer Res; 1980 Oct 11; 40(10):3455-8. PubMed ID: 7002286
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Strain difference in delayed-type hypersensitivity to BCG in mice: role of splenic adherent cells in the primary immune response.
    Nakamura RM, Tanaka H, Tokunaga T.
    Immunology; 1982 Dec 11; 47(4):729-31. PubMed ID: 6216204
    [No Abstract] [Full Text] [Related]

  • 31. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis.
    Feng CG, Palendira U, Demangel C, Spratt JM, Malin AS, Britton WJ.
    Infect Immun; 2001 Jun 11; 69(6):4174-6. PubMed ID: 11349095
    [Abstract] [Full Text] [Related]

  • 32. BCG and cancer (first of two parts).
    Bast RC, Zbar B, Borsos T, Rapp HJ.
    N Engl J Med; 1974 Jun 20; 290(25):1413-20. PubMed ID: 4364286
    [No Abstract] [Full Text] [Related]

  • 33. A guinea pig model for tumor immunology. A summary.
    Rapp HJ.
    Isr J Med Sci; 1973 Mar 20; 9(3):366-74. PubMed ID: 4122812
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effect of Bacillus Calmette-Guérin on mammary tumor formation and cellular immunity in dimethylbenz(a)anthracene-treated rats.
    Piessens WF, Heimann R, Legros N, Heuson JC.
    Cancer Res; 1971 Aug 20; 31(8):1061-5. PubMed ID: 4938027
    [No Abstract] [Full Text] [Related]

  • 36. A direct relationship between immune competence and the subcutaneous growth rate of a malignant murine lung tumor.
    Yuhas JM, Pazmino NH, Proctor JO, Toya RE.
    Cancer Res; 1974 Apr 20; 34(4):722-8. PubMed ID: 4360837
    [No Abstract] [Full Text] [Related]

  • 37. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J.
    Cancer Res; 1983 Dec 20; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.